As our valued providers continue to battle COVID-19 on the frontlines, we’d like to share useful resources we come across from the sidelines: for one, the Assessment of Evidence for COVID-19-Related Treatments recently published by the American Society of Health System Pharmacists (ASHP).
The table covers class, rationale, trials, and dosage information for antiviral agents such as lopinavir and ritonavir, chloroquine phosphate, and hydroxychloroquine; supporting agents such as corticosteroids, methylprednisolone, and nitrous oxide; and other agents like ACE inhibitors and ibuprofen.
To view the pdf of the chart, visit the ASHP Coronavirus Resource Center and select Assessment of Evidence for COVID-19-Related Treatment.
ASHP has also granted open access to many of their member resources and has urged members of the healthcare community to share this within your networks. This content can be found through the ASHP open resources page and includes “section and topical Resource Centers (e.g., Emergency Preparedness, Geriatrics, Inpatient Care), relevant webinars and online programs (e.g., infectious diseases, flu, disaster and mass casualty preparedness, and well-being and resilience), and select AJHP articles.” Additionally, public access to AHFS Drug Information is available for a limited time with the username email@example.com and password covid-19.”
“ASHP represents pharmacists who serve as patient care providers in acute and ambulatory settings. The organization’s nearly 55,000 members include pharmacists, student pharmacists, and pharmacy technicians. For more than 75 years, ASHP has been at the forefront of efforts to improve medication use and enhance patient safety.”
ASHP Disclaimer About the Assessment of Evidence for COVID-19-Related Treatments
“The information contained in this evidence table is emerging and rapidly evolving because of ongoing research and is subject to the professional judgment and interpretation of the practitioner due to the uniqueness of each medical facility’s approach to the care of patients with COVID-19 and the needs of individual patients. ASHP provides this evidence table to help practitioners better understand current approaches related to treatment and care. ASHP has made reasonable efforts to ensure the accuracy and appropriateness of the information presented. However, any reader of this information is advised ASHP is not responsible for the continued currency of the information, for any errors or omissions, and/or for any consequences arising from the use of the information in the evidence table in any and all practice settings. Any reader of this document is cautioned that ASHP makes no representation, guarantee, or warranty, express or implied, as to the accuracy and appropriateness of the information contained in this evidence table and will bear no responsibility or liability for the results or consequences of its use.”